Everand Logo

Welcome to Everand!

  • STAT

    Pfizer spends billions to develop new drugs. It’s not satisfied. So it’s launching a startup

    Pharma giant Pfizer is launching a six-person spinoff to develop new drugs in a bid to capture the scrappy intensity of biotech startups.
    by Damian Garde Sep 25, 2017 3 minutes

    There’s a popular theory about the limitations of global pharma companies: For all their skyscrapers and strategy reviews and private jets, they’re simply too knotted up in bureaucracy to realize how many great drugs are gathering dust in their vaults.

    Now, the biggest of Big Pharma is out do do something about that. Pfizer, home to nearly 100,000 employees, on Monday announced the launch of a six-person startup to develop new drugs.

    This may seem odd

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
    When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
    STAT1 min read
    STAT+: Element Biosciences, An Illumina Rival, On Its Genomics Ambitions — And Why It Hasn’t Gone Public
    Element Biosciences' modest growth comes at a time when some other players are struggling in a sequencer market dominated by Illumina.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Boy Dying In Pfizer Trial; AstraZeneca Yanking Covid Shot, And More
    A young boy died in a clinical trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy, about a year after receiving the therapy.

    Related Books & Audiobooks